EP 2194978 A1 20100616 - USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
Title (en)
USE OF GESTAGENS IN COMBINATION WITH (6S)-5-METHYLTETRAHYDROFOLATE FOR THE THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPY SIDE EFFECTS AND THE REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS IN CASE OF PREGNANCY
Title (de)
VERWENDUNG VON GESTAGENEN IN KOMBINATION MIT (6S)5-METHYLTETRAHYDROFOLAT ZUR THERAPIE DER ENDOMETRIOSE MIT GLEICHZEITIGER VERMINDERUNG VON THERAPIE-NEBENWIRKUNGEN SOWIE DER VERMINDERUNG DES RISIKOS ANGEBORENER FEHLBILDUNGEN BEI EINTRITT EINER GRAVIDITÄT
Title (fr)
UTILISATION DE GESTAGÈNES EN COMBINAISON AVEC DU (6S)-5-MÉTHYLTÉTRAHYDROFOLATE POUR LE TRAITEMENT DE L'ENDOMÉTRIOSE AVEC RÉDUCTION SIMULTANÉE D'EFFETS SECONDAIRES DU TRAITEMENT ET DIMINUTION DU RISQUE DE MALFORMATIONS CONGÉNITALES EN DÉBUT DE GROSSESSE
Publication
Application
Priority
- EP 2008006253 W 20080730
- EP 07016642 A 20070824
- EP 08785200 A 20080730
Abstract (en)
[origin: EP2027855A1] Use of gestagen in combination with (6S)-5-methyltetrahydrofolate for the production of a pharmaceutical preparation (I) for the therapy of endometriosis with simultaneous reduction of therapy side-effects, preferably negative effects on bone density or bone metabolism, osteoporosis risk, risk of congenital malformations and pregnancy complications in early stage of pregnancy, is claimed, where the daily dose of the gestagen corresponds to at least an ovulation inhibiting dose to maximally dual of the ovulation inhibiting dose. ACTIVITY : Gynecological; Osteopathic. MECHANISM OF ACTION : None given.
IPC 8 full level
A61K 31/195 (2006.01); A61K 31/495 (2006.01); A61K 31/505 (2006.01); A61K 31/519 (2006.01); A61K 31/565 (2006.01); A61K 31/57 (2006.01); A61P 15/02 (2006.01); A61P 15/12 (2006.01); A61P 15/18 (2006.01); A61P 19/10 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP)
A61K 31/195 (2013.01); A61K 31/495 (2013.01); A61K 31/505 (2013.01); A61K 31/519 (2013.01); A61K 31/565 (2013.01); A61K 31/57 (2013.01); A61K 45/06 (2013.01); A61P 5/02 (2017.12); A61P 5/24 (2017.12); A61P 5/34 (2017.12); A61P 15/00 (2017.12); A61P 15/02 (2017.12); A61P 15/12 (2017.12); A61P 15/18 (2017.12); A61P 19/10 (2017.12); A61P 43/00 (2017.12)
Citation (search report)
See references of WO 2009027003A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA MK RS
DOCDB simple family (publication)
EP 2027855 A1 20090225; AR 070023 A1 20100310; AU 2008291406 A1 20090305; BR PI0815756 A2 20150218; CA 2696030 A1 20090305; CL 2008002485 A1 20091120; CN 101784271 A 20100721; EA 201000338 A1 20100830; EP 2194978 A1 20100616; JP 2010536808 A 20101202; KR 20100047872 A 20100510; MX 2010002190 A 20100317; PA 8793901 A1 20090423; PE 20090608 A1 20090612; TW 200930377 A 20090716; UY 31306 A1 20081128; WO 2009027003 A1 20090305; ZA 201002035 B 20120926
DOCDB simple family (application)
EP 07016642 A 20070824; AR P080103662 A 20080822; AU 2008291406 A 20080730; BR PI0815756 A 20080730; CA 2696030 A 20080730; CL 2008002485 A 20080822; CN 200880104242 A 20080730; EA 201000338 A 20080730; EP 08785200 A 20080730; EP 2008006253 W 20080730; JP 2010521333 A 20080730; KR 20107003890 A 20080730; MX 2010002190 A 20080730; PA 8793901 A 20080822; PE 2008001424 A 20080822; TW 97132227 A 20080822; UY 31306 A 20080822; ZA 201002035 A 20100323